The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS

Clinical Breast Cancer · Published 2026-08-01 · DOI 10.1016/j.clbc.2026.07.031

Free full text

Authors (16)

Sarah P. Hudson-Phillips, Akriti Nanda, Mohamed Attia, Wadha Al Yaqout, Evelyn Marshall, Jennifer E. Rusby, Katherine Krupa, Peter A. Barry, Marios Konstantinos Tasoulis, Gerald Gui, Radhika Merh, Bethany Torr, Zoe Kemp, Angela George, Clare Turnbull, Rachel L. O’Connell

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Hudson-Phillips, S., Nanda, A., Attia, M., et al. (2026). The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.031

Related articles